Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 8:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 288 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Prevention of Sexually Transmitted Infections Clear all

Conditions: HIV/AIDS
Interventions: Genvoya; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Highly Active Antiretroviral Therapy (HAART)-Related Nausea and Vomiting, HIV Infections
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 36
States / cities: Bakersfield, California • Fresno, California • Los Angeles, California + 27 more

Conditions: HIV/AIDS
Interventions: JIC; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 14 Years to 22 Years
Enrollment: 8,270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19
Interventions: AntiCov-220, AntiCov-220 (placebo); Drug
Lead sponsor: Nguyen Thi Trieu, MD; Individual
Eligibility: 16 Years to 82 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Wilmington, Delaware

Conditions: Sexually Transmitted Infections, Gay, Pre Exposure Prophylaxis
Interventions: Quantitative survey, HIV and STI testing, Qualitative Assessment; Behavioral · Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 675 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: San Diego, California • Atlanta, Georgia • Chicago, Illinois

Conditions: Sexually Transmitted Infection
Interventions: Doxycycline; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infection
Interventions: Tenofovir Disoproxil Fumarate 300 mg daily; Drug
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years to 29 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1992
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: HIV, STI
Interventions: PrEP discontinuation intervention, Offering of on-demand oral PrEP, Offering of STI PEP, Injectable PrEP; Behavioral · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more

Conditions: HPV Vaccination, Uptake Vaccination, Series Completion
Interventions: PREVENT; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Human Immunodeficiency Virus
Interventions: 3BNC117, 10-1074, Placebo; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate; Drug
Lead sponsor: Fisons; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV/AIDS, Contraception
Interventions: tenofovir/emtricitabine, DMPA; Combination Product · Drug
Lead sponsor: Sharon Achilles; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV, Gonorrhea, Chlamydia
Interventions: Keep It Up!, HIV Knowledge Control; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 901 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Atlanta, Georgia • Chicago, Illinois • New York, New York

Conditions: Ebola Virus Disease, Marburg Virus Disease
Interventions: cAd3-Marburg, cAd3-EBO-S; Biological
Lead sponsor: Albert B. Sabin Vaccine Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Human Immunodeficiency Virus
Interventions: Increase condom use; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Male only
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Herpes Simplex
Interventions: Valaciclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV/AIDS
Interventions: Waitlist, Intervention; Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose, gp140 DP High-dose, Placebo; Biological · Drug
Lead sponsor: Janssen Vaccines & Prevention B.V.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 393 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • Rockville, Maryland + 2 more

Conditions: HIV Infections
Interventions: Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2005
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sexual Transmission of Infection
Interventions: HIV prevention intervention, Diet and Nutrition; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 29 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: HIV Infections
Interventions: Lenacapavir Injection, Emtricitabine/tenofovir disoproxil fumarate (F/TDF), Emtricitabine/tenofovir alafenamide (F/TAF), Cabotegravir (CAB), Lenacapavir Tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 3,000 participants
Timeline: 2026 – 2029
U.S. locations: 39
States / cities: Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Ganciclovir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 19
States / cities: Berkeley, California • Los Angeles, California • San Diego, California + 12 more

Search by objective public record fields.

Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Considered for Future On-demand Peri-exposure HIV Prophylaxis Regimens

Dronabinol Versus Placebo in Treatment and Prevention of Highly Active Anti-Retroviral Therapy (HAART)-Related Nausea and Vomiting

Assessing the Impact of an Educational HIV Prevention Intervention in Zambia

Prevention and Treatment of Patient Before, During, and After Covid-19 Infection

HIV/STD Risk and PrEP Implementation Messaging Among Gay, Bisexual, and Other Men Who Have Sex With Men

Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens

Botswana Tenofovir Oral HIV Prophylaxis Trial

A Study of Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia

Parrying the Pitfalls of PrEP: Project PEACH

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

PREVENT HPV -Related Cancers Trial

3BNC117 and 10-1074 in HIV Uninfected Adults

An Open Label Study to Evaluate the Long-Term Safety and Effectiveness of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

HIV Prevention in the Primary Care Setting

Valaciclovir to Prevent Transmission of Herpes Simplex Virus

Acceptability, Feasibility and Preliminary Impact of OurPlan, an mHealth HIV Prevention Intervention for Male Couples

Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention

The Safety of Nevirapine When Given to Breast-Feeding Babies From Birth to Age 6 Months

HIV Prevention Intervention for Young Transgender Women

Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus